Cargando…

Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients

Objectives: To analyze the characteristics and the predictive factors of the use of rituximab and belimumab in daily practice in patients from the inception cohort Registro Español de Lupus (RELES). Material and methods: The study included 518 patients. We considered patients treated with biologics...

Descripción completa

Detalles Bibliográficos
Autores principales:	Capdevila, O., Mitjavila, F., Espinosa, G., Caminal-Montero, L., Marín-Ballvè, A., González León, R., Castro, A., Canora, J., Pinilla, B., Fonseca, E., Ruiz-Irastorza, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456702/ https://www.ncbi.nlm.nih.gov/pubmed/37629652 http://dx.doi.org/10.3390/medicina59081362

Ejemplares similares

The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
por: Abid, Naushad, et al.
Publicado: (2023)

Letter in reply: Crusted scabies mimicking a lupus flare after rituximab and belimumab
por: Androsov, Grigoriy, et al.
Publicado: (2021)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
por: Atisha‐Fregoso, Yemil, et al.
Publicado: (2020)

Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents
por: Wise, Leanna M., et al.
Publicado: (2020)

An update on belimumab for the treatment of lupus
por: Thanou-Stavraki, Aikaterini, et al.
Publicado: (2011)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies
por: Petricca, Luca, et al.
Publicado: (2020)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)

De novo lupus nephritis during treatment with belimumab
por: Parodis, Ioannis, et al.
Publicado: (2020)

A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE
por: van Dam, Laura S, et al.
Publicado: (2020)

Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results
por: Kraaij, Tineke, et al.
Publicado: (2020)

Off-label use of rituximab for systemic lupus erythematosus in Europe
por: Rydén-Aulin, Monica, et al.
Publicado: (2016)

New treatment options for lupus – a focus on belimumab
por: Chiche, Laurent, et al.
Publicado: (2012)

Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
por: Guzman, Marla, et al.
Publicado: (2020)

Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus
por: Plüß, Marlene, et al.
Publicado: (2020)

Effect of Belimumab on Preventing de novo Renal Lupus Flares
por: Parodis, Ioannis, et al.
Publicado: (2023)

A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome
por: Mariette, Xavier, et al.
Publicado: (2022)

Efficacy of belimumab monotherapy in high infectious risk patient affected by lupus nephritis
por: D’Alessandro, Roberto, et al.
Publicado: (2021)

Belimumab: First targeted biological treatment for systemic lupus erythematosus
por: Dubey, Ashok K., et al.
Publicado: (2011)

Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis
por: Frieri, Marianne, et al.
Publicado: (2015)

Belimumab in Lupus Nephritis: A Systematic Review and Meta-Analysis
por: Shrestha, Sanjeev, et al.
Publicado: (2021)

The Role of Belimumab in Systemic Lupus Erythematosis: A Systematic Review
por: Joy, Ashna, et al.
Publicado: (2022)

Urine proteomic insights from the belimumab in lupus nephritis trial
por: Weeding, Emma, et al.
Publicado: (2022)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
por: Kirou, Kyriakos A., et al.
Publicado: (2022)

High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients
por: Fabris, Martina, et al.
Publicado: (2022)

Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial
por: van Schaik, Mieke, et al.
Publicado: (2022)

Real life experience on the effect of Belimumab in patients with active systemic lupus
por: Scheinberg, Morton, et al.
Publicado: (2014)

Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus
por: Zhou, Xuan, et al.
Publicado: (2021)

Belimumab in childhood systemic lupus erythematosus: A review of available data
por: Chen, Feng, et al.
Publicado: (2022)

Treatment Using Both Voclosporin and Belimumab in Four Patients With Lupus Nephritis
por: Baum, Rebecca, et al.
Publicado: (2023)

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
por: van Vollenhoven, Ronald F, et al.
Publicado: (2012)

Pharmacogenetic analysis of belimumab fails to identify robust genetic predictors of efficacy in lupus
por: St Jean, Pamela L., et al.
Publicado: (2019)

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort
por: Ruiz-Irastorza, G, et al.
Publicado: (2016)

Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab
por: Hassan, Sabih Ul, et al.
Publicado: (2020)

Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus
por: Schwarting, A, et al.
Publicado: (2016)

Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study
por: Touma, Zahi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_96fpf5g040vg7ntthqdu3nlcs5